Literature Highlights

Each week, we provide COVID-19 research article summaries and the main highlights in an infographic. Please come back weekly for more updated pandemic infographic highlights covering diagnosis, risk factors, treatment, and more.

  • Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

  • Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial

  • Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer

  • Subcutaneous REGEN-COV antibody combination to prevent COVID-19

  • Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant

  • Neutralizing capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

  • Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines

  • Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platfom trial

  • Tackling COVID-19 with neutralizing monoclonal antibodies

  • Myocarditis following COVID-19 mRNA vaccination

  • Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicenter, randomized, controlled trial

  • 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study

  • Interim Results of a Phase 1–2a Trial of Ad26.COV2.S COVID-19 Vaccine

  • ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

  • Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons

  • Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia

  • Interleukin-6 Receptor Antagonists in Critically III Patients with COVID-19

  • Prospective Mapping of Viral Mutations That Escape Antibodies Used to Treat COVID-19

  • Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults

  • Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

  • Interim Results of a Phase 1-2a Trial of Ad26.COV2.S COVID-19 Vaccine

  • Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19

  • Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Trial

  • REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19

  • Pre-pandemic Psychiatric Disorders and Risk of COVID-19: A UK Biobank Cohort Analysis

  • Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact

  • SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19

  • Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates

  • Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

  • Therapeutic Versus Prophylactic Anticoagulation for Severe COVID-19: A Randomized Phase II Clinical Trial (HESACOVID)

  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

  • Effects of COVID-19 on the Nervous System

  • COVID-19 Vaccine: A Comprehensive Status Report

  • Extrapulmonary Manifestations of COVID-19

  • Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis

  • Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report

  • Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-19: A Preliminary Report of a Phase 1/2, Single-Blind, Randomized Controlled Trial

  • An mRNA vaccine Aganist SARS-CoV-2 – Preliminary Report

  • Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial

  • Pilot Prospective Open, Single-arm Multicentre Study on Off-label Use of Tocilizumab in Patients With Severe COVID-19

  • Observational Study of Hydroxychlaraquine in Hospitalized Patients with COVID-19

  • Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

  • Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital

  • Biomarkers Associated with COVID-19 Disease Progression

  • Remdesivir for the Treatment of COVID-19 – Preliminary Report

  • A Comparative Study on the Clinical Features of COVID-19 Pneumonia to Other Pneumonias

  • Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

  • Candidate drugs against SARS-CoV-2 and COVID-19

Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill